Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 657-659

  Ziemer, Mirjana ^a   Koukoulioti, Eleni ^a   Beyer, Susanne ^a   Simon, Jan C ^a   Berg, Thomas ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BUDESONIDE; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; URSODEOXYCHOLIC ACID; GLUCOCORTICOID; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

DISEASE SEVERITY; HUMAN; LETTER; METASTATIC MELANOMA; PRIORITY JOURNAL; TOXIC HEPATITIS; AGED; AUTOIMMUNE DISEASE; CASE REPORT; CHEMICALLY INDUCED; FEMALE; IMMUNOLOGY; LIVER FUNCTION TEST; MELANOMA; PROCEDURES; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; AUTOIMMUNE DISEASES; BUDESONIDE; CHEMICAL AND DRUG INDUCED LIVER INJURY; FEMALE; GLUCOCORTICOIDS; HUMANS; LIVER FUNCTION TESTS; MELANOMA; NIVOLUMAB; TREATMENT OUTCOME;

EID: 85009286690     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.11.015     Document Type: Letter

References (17)

1. [1] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
2. [2] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2015), 320–330.
3. [3] Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
4. [4] Sangro B, Melero I, Yau T et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study. In:Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO); June 3-7, 2016; Chicago, IL, USA, poster 4078.
5. [5] El-Khoueiry, A.B., Melero, I., Crocenzi, T.S., et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol, 33, 2015.
6. [6] Kähler, K.C., Hassel, J.C., Heinzerling, L., et al. Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma. J Dtsch Dermatol Ges 14 (2016), 662–681.
7. [7] Teply, B.A., Lipson, E.J., Identification and management of toxicities from immune checkpoint-blocking drugs. Oncology (Willston Park) 28 (2014), 30–38.
8. [8] Johncilla, M., Misdraji, J., Pratt, D.S., et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol 39 (2015), 1075–1084.
9. [9] Kim, K.W., Ramaiya, N.H., Krajewski, K.M., et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 31 (2013), 1071–1077.
10. [10] Weber, J., Antonia, S.J., Topalian, S., et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol, 33, 2015.
11. [11] Keytruda. EPAR – Product Information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003820/human_med_001886.jsp&mid=WC0b01ac058001d124 (last visited 15.07.2016).
12. [12] Opdivo: EPAR – Product Information. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003985/human_med_001876.jsp&mid=WC0b01ac058001d124 (last visited 15.07.2016).
13. [13] Manns, M.P., Woynarowski, M., Kreisel, W., et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 139 (2010), 1198–1206.
14. [14] Wree, A., Dechene, A., Herzer, K., et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 84 (2011), 54–59.
15. [15] Nakamura, K., Yoneda, M., Yokohama, S., et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 13 (1998), 490–495.
16. [16] Czaja, A.J., Carpenter, H.A., Lindor, K.D., Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomizes placebo-controlled treatment trial. Hepatology 30 (1999), 1381–1386.
17. [17] Hu, J., Zhang, Q., Ren, X., et al. Efficacy and safety of acetylcysteine in “non-acetaminophen” acute liver failure: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol 39 (2015), 594–599.